Trials / Completed
CompletedNCT01047540
Safety and Efficacy Study for a New Antiviral Drug to Treat Genital Herpes Type 2
A Double-blind Randomized Placebo Controlled Dose-finding Trial to Investigate Different Doses of a New Antiviral Drug in Subjects With Genital HSV Type 2 Infection
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 156 (actual)
- Sponsor
- AiCuris Anti-infective Cures AG · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The aim of the study is to find out whether AIC316 is safe and efficacious for the prevention of reactivation of genital herpes
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AIC316 | Oral administration |
| DRUG | AIC316 | Oral administration |
| DRUG | AIC316 | Oral administration |
| DRUG | AIC316 | Oral administration |
| DRUG | Placebo | Oral administration |
Timeline
- Start date
- 2010-03-01
- Primary completion
- 2010-12-01
- Completion
- 2011-03-01
- First posted
- 2010-01-13
- Last updated
- 2023-04-21
- Results posted
- 2022-02-04
Locations
6 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01047540. Inclusion in this directory is not an endorsement.